The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Subscribe To Our Newsletter & Stay Updated
